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Background
Standard treatment for stage I or non-bulky stage II diffuse large B-cell lymphoma (DLBCL) 
has been either a brief course of chemotherapy plus involved-field radiotherapy (IFRT) 
or prolonged cycles of chemotherapy. The introduction of rituximab has necessitated 
re-evaluation of the treatment for limited disease (LD) DLBCL.
Methods
Thirty-nine LD DLBCL patients (median age, 52 years; range, 24-85) treated with ritux-
imab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were 
retrospectively analyzed. Treatment outcomes were evaluated, and toxicity, event-free 
survival (EFS), and overall survival (OS) were compared according to the treatment and 
risk factors.
Results
The median follow-up duration was 34.6 months (range, 9.1-65.4). The 3-year EFS and 
OS were 76.0% and 86.0%, respectively. Among the 36 patients who underwent either 
3-4 cycles of R-CHOP followed by IFRT (N=22) or 6-8 cycles of R-CHOP (N=14), there 
was no difference in the 3-year EFS (79.4% vs. 71.6%, P=0.638) and 3-year OS (85.7% 
vs. 92.9%, P=0.732). Severe neutropenia and neutropenic fever were more frequent in 
patients treated with R-CHOP alone, with 1 treatment-related mortality. Among the IFRT 
patients, 1 required hospital admission for IFRT-related complications. No events or 
deaths were reported among patients without adverse risk factors.
Conclusion
The difference in outcomes between the 2 treatment options was not significant. Analysis 
of treatment outcomes suggested that baseline characteristics and expected toxicities 
should be considered in LD DLBCL treatment. Further studies are needed to define the 
optimal treatment in the rituximab era.
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INTRODUCTION
  Treatment options for diffuse large B-cell lymphoma 
(DLBCL), the most common type of non-Hodgkin’s lympho-
ma [1], differ for patients with limited disease compared 
to those with advanced disease [2]. Therefore, a clear defi-
nition of “limited disease” is required. In previously published 
studies, limited disease has also been referred to as “localized 
disease” [3, 4], and the terms “early-stage” or “low-stage” 
h a v e  b e e n  u s e d .  T h i s  c a t e g o r y  o f  d i s e a s e  i s  d e f i n e d  a s  
non-Hodgkin’s lymphoma (NHL) of Ann Arbor stage I and 
non-bulky stage II. Bulky disease is defined as any mass 
with a maximum diameter greater than 10 cm or any media-
stinal mass exceeding 1/3 of the maximum transthoracic 
diameter [2]. Because patients with bulky stage II lymphoma 
have a prognosis similar to those with stage III or IV disease, 
they usually are regarded as having advanced disease [2].Korean J Hematol 2010;45:253-9.
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  The stage-modified International Prognostic Index (IPI) 
has proven useful for studies of limited disease in patients 
with NHL [3, 5]. Adverse risk factors of stage-modified IPI 
include the following 4 clinical parameters: Eastern 
Cooperative Oncology Group Performance Status 2 to 4, 
non-bulky stage II, age ＞60 years, and elevated level of 
serum lactose dehydrogenase. Patients with no adverse risk 
factors have been reported to have an excellent prognosis 
when treated with 3 cycles of doxorubicin-containing combi-
nation chemotherapy plus involved-field radiation therapy 
(IFRT) [6]. In a study reported by the British Columbia 
Cancer Agency, the 5-year and 10-year overall survival (OS) 
rates were 97% and 90%, respectively [5]. Excellent prognosis 
was achieved regardless of the treatment strategy, including 
a brief course of combination chemotherapy with cyclo-
phosphamide, doxorubicin, vincristine, and prednisolone 
(CHOP) plus IFRT, in addition to 8 cycles of CHOP [3], 
or an aggressive combination regimen containing doxor-
ubicin [7].
  For patients with limited disease NHL and any adverse 
risk factor, both chemotherapy followed by radiotherapy 
and chemotherapy alone have been used. These treatment 
options were based on the results of numerous previous 
studies [8-11]. In the early 1980s, chemotherapy followed 
by subsequent radiotherapy was found to be superior to 
radiotherapy alone, which was the standard treatment at 
that time [11]. During the same period, chemotherapy alone 
was also accepted as an effective treatment option for limited 
disease NHL [8], and a brief course of chemotherapy followed 
by IFRT was further tested and confirmed to be effective 
[9, 10]. 
  The emergence of rituximab, a monoclonal antibody to 
CD20, for clinical treatment has substantially improved the 
EFS and OS in both elderly [12] and young [13] patients 
with DLBCL. Addition of rituximab to 3 cycles of CHOP 
chemotherapy with subsequent IFRT has been evaluated 
and was shown to be effective in a phase II study [14]. 
Although the current National Comprehensive Cancer 
Network Clinical Practice Guidelines for NHL recommends 
both 3 cycles of rituximab with CHOP (R-CHOP) plus IFRT, 
and 6-8 cycles of R-CHOP with or without subsequent IFRT 
[15], the recommendations are based on data and practices 
of the pre-rituximab era. No study has re-evaluated the 2 
treatment options in patients with limited disease DLBCL. 
In this study, the efficacy and tolerability of the 2 treatment 
options in limited disease DLBCL patients treated with 
R-CHOP were compared.
MATERIALS AND METHODS
  Data were collected and reviewed from DLBCL patients 
treated with R-CHOP at a single institution, Gachon Univer-
sity Gil Hospital (GUGH), between June 2004 and September 
2009. Patients with Ann Arbor stage I or non-bulky stage 
II were selected for this study, and were retrospectively 
analyzed. Patients were included in the study if they had 
histological confirmation of DLBCL according to the World 
Health Organization (WHO) criteria without any previous 
treatment for the lymphoma. Patients with DLBCL originat-
ing from transformation of an indolent lymphoma, with 
primary involvement of the central nervous system or with 
human immunodeficiency virus-associated lymphoma were 
excluded from the analysis. The institutional review board 
at GUGH granted permission for this retrospective study.
  A cycle of R-CHOP consisted of 375 mg/m
2 of rituximab, 
on day 1 of each cycle and a combination of 750 mg/m
2 
of cyclophosphamide, 50 mg/m
2 of doxorubicin and 1.4 
mg/m
2 of vincristine (maximal dose of 2 mg), all on day 
1. Patients also received 100 mg/day of prednisolone PO 
for 5 days. The immunochemotherapy cycle was repeated 
every 21 days. Granulocyte colony stimulating factor support 
was limited to secondary neutropenia prophylaxis.
  IFRT consisted of 30-36 Gy for patients achieving a com-
plete response (CR), with a boost volume to a maximum 
of 50-55 Gy for patients failing to achieve a CR, in daily 
fractions of 1.8 Gy (5 days a week) in predetermined standard 
ports involving only the lymph node region(s) or organs 
affected by overt disease and calculated at the midplane 
of the target volume or at 3-cm depth for the supraclavicular 
regions. Most IFRT treatments were completed in 4-5 weeks. 
The duration of treatment depended on the dose delivered. 
  Response evaluation for patients with DLBCL was per-
formed 3 months after treatment completion by spiral com-
puted tomography (CT) of the lymphoma-involved area. 
Positron emission tomography-CT could also be used to con-
firm the final response status. Responses were evaluated ac-
cording to the International Workshop criteria [16]. Follow- 
up physical examinations and laboratory screenings were 
performed every 3 months for the first 2 years, then every 
6 months for 3 years, and annually thereafter. 
  EFS was defined as survival free of progression, relapse, 
or death from lymphoma or treatment-related toxicity. OS 
was defined as survival free of death from any cause. Survival 
was calculated using the Kaplan-Meier method and compared 
by log rank test. Probability values of less than 0.05 were 
considered statistically significant. Fisher’s exact test was 
used to compare baseline characteristics between patients 
treated with subsequent IRFT and those treated with addi-
tional R-CHOP. SPSS software version 15.0 (SPSS Inc., 
Chicago, IL, USA) was used for all statistical analyses.
RESULTS
1. Patients 
  Among 87 patients treated with R-CHOP therapy, 43 pa-
tients had Ann Arbor stage I or II DLBCL (49.4%). Because 
4 of the 43 patients had a bulky mass at initial presentation, 
39 patients (44.8%) were classified as limited disease DLBCL. 
The 4 patients with bulky stage II disease received 6-8 cycles 
of R-CHOP with (1 patient) or without (3 patients) IFRT. 
  The median age of the patients with limited disease was 
52 years (range, 24-85). Thirty-six of the 39 patients with Korean J Hematol 2010;45:253-9.
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Table 1. Patient characteristics.
Clinical characteristics
Subsequent
IFRT 
(N=22)
Additional
R-CHOP 
(N=4)
P 
Median age (range) 61 (24-85) 50 (35-80)
Age＞60 years 0.085
Yes 11 (50%) 3 (21.4%)
No 11 (50%) 11 (78.6%)
Sex 0.349
 Male 9 (40.9%) 4 (28.6%)
 Female 13 (59.1%) 10 (71.4%)
ECOG performance status 0.51
 0 9 (40.9%) 4 (28.6%)
 1 12 (54.5%) 8 (57.1%)
 2 1 (4.5%) 2 (14.3%)
Lactate dehydrogenase 0.658
 Elevated 3 (13.6%) 3 (21.4%)
 Not elevated 19 (86.4%) 11 (78.6%)
B symptom 0.228
 Yes 5 (22.7%) 1 (7.1%)
 No 17 (77.3%) 13 (92.9%)
Any risk factor 0.110
 Yes 18 (81.8%) 8 (57.1%)
 No 4 (18.2%) 6 (42.9%)
Radiation therapy
 Median delivered dose 36.0 Gy −
 (Range) (34.2-54.0) −
 Region
    Head and neck 
    Axilla
    Abdomen and pelvis
    Orbit
12
3
5
2
Abbreviations: IFRT, involved-field radiation therapy; R-CHOP, 
combination immunochemotherapy consisting of rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisolone; ECOG, 
Eastern Cooperative Oncology Group.
stage I or non-bulky stage II disease underwent either 3-4 
cycles of R-CHOP followed by IFRT (N=22) or 6-8 cycles 
of R-CHOP alone (N=14). Three patients belonged to neither 
treatment group. A male patient with stage I disease and 
without any adverse factors initially presented with isolated 
left inguinal lymph node enlargement. He was diagnosed 
with DLBCL on the basis of an excision biopsy of the lymph 
node, and after 4 cycles of R-CHOP, he had no lesion that 
required IRFT because of complete excision. A second 73 
year-old male patient with no adverse risk factors, except 
for age, died of treatment-related mortality (TRM) after the 
third cycle of R-CHOP. A third patient with non-bulky 
stage II DLBCL refused further treatment after the third 
cycle of R-CHOP immunochemotherapy. 
  There was 1 TRM in the 6-8 R-CHOP cycle group. A 
74-year-old female patient who had all 4 adverse risk factors 
died of severe pneumonia after the sixth cycle of R-CHOP. 
The baseline characteristics of b o t h  g r o u p s  w e r e  s i m i l a r  
(Table 1).
2. Treatment outcomes
  During the median follow-up period of 34.6 months (range, 
9.1-65.4) for patients with limited disease DLBCL, 8 patients 
(20.5%) experienced an event and 5 of them (12.8%) even-
tually died. Among these 8 patients, the reported events 
were relapse or progression of the lymphoma (5 patients), 
TRM (2 patients), 1 death that was not related to treatment 
or lymphoma, and sudden cardiac arrest due to acute my-
ocardial infarction (1 patient). 
  Table 2 shows the disease presentation and treatment out-
comes of 36 patients who underwent either subsequent IFRT 
or additional R-CHOP. Most patients achieved complete re-
sponse (CR) or CR unconfirmed (CRu) irrespective of the 
treatment option. Only 2 patients in each group showed 
partial response (PR) in the interim analysis performed after 
the initial 3-4 cycles of R-CHOP and only 1 patient, with 
thyroid lymphoma, had a PR after additional R-CHOP. 
  Three patients treated with IFRT and 2 patients treated 
with additional R-CHOP relapsed. All 3 patients treated 
with IFRT had relapsed because the lesion was outside the 
previous radiation field. 
  The 3-year EFS and OS were 76.0% and 86.0%, respec-
tively. The median EFS and OS have not yet been reached 
(Fig. 1).
3. Comparison of treatment-related toxicities
  Patients who underwent 6-8 cycles of R-CHOP alone 
showed more frequent grade 3 or 4 neutropenia, probably 
due to the additional cycles of R-CHOP therapy. Among 
the 36 patients who underwent either treatment option, 
8 patients (22.2%) reported neutropenic fever and required 
admission for intravenous (IV) antibiotic administration (3 
of the 22 patients treated with IFRT and 5 of the 14 patients 
treated with further R-CHOP) during their first 3-4 cycles 
of R-CHOP. After completion of the initial R-CHOP, 6 of 
the 14 patients treated with additional immunochemo-
therapy reported neutropenic fever that required hospital 
admission and IV antibiotics. Four of the 6 patients experi-
enced recurrent neutropenic fever after their first 3-4 cycles 
of R-CHOP, even though they all had a 25% dose reduction 
of cyclophosphamide and doxorubicin after the previous oc-
currence of neutropenic fever. In contrast, among the pa-
tients treated with subsequent IFRT, no patient had recurrent 
neutropenic fever. However, 1 of the 22 patients treated 
with subsequent IFRT required admission for grade 3 mucosi-
tis after radiation (Table 3). There was no TRM in the IFRT 
group, and there was 1 TRM in the continued immunochem-
otherapy group.
4. Comparison of survival according to treatment option
  The 3-year EFS among patients who underwent 3-4 cycles 
of R-CHOP followed by IFRT and the long course of R-CHOP 
alone was 79.4% and 71.6%, respectively. Therefore, there 
w a s  n o  d i f f e r e n c e  i n  E F S .  I n  a d d i t i o n ,  t h e  3 - y e a r  O S  o f  
patients treated with R-CHOP followed by IFRT and the 
long course of R-CHOP alone was 85.7% and 92.9% re-
spectively, and the difference was not significant by log-rank 
test (Fig. 2).Korean J Hematol 2010;45:253-9.
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Table 2. Profile of patients’ tumor response and pattern of relapse.
Patient Primary site (s) R1
a) R2
b) Relapse
Relapse
site (s)
Patient Primary site (s) R1 R2 Relapse
Relapse
 site (s)
RT
c)1 (M/65) Unilateral testis CR CR No − RT19 (M/58) Multiple neck nodes CRu CRu No −
RT2 (M/64) An axillary node CR CR No − RT20 (F/76) Tonsil CRu CRu Yes Mediastinal
 nodes
RT3 (M/85) Multiple neck nodes CRu CRu No − RT21 (F/73) Tonsil PR CRu Yes Lung
RT4 (F/73) Multiple neck nodes CRu CR Yes Brain RT22 (F/49) Unilateral ocular adnexa CR CR No −
RT5 (F/71) Uterus PR CR No − CT
d)1 (M/49) Terminal ileum CR CR No −
RT6 (F/24) Terminal ileum CR CR No − CT2 (F/47) A neck node CR CR No −
RT7 (F/38) Mediastinal nodes CRu CR No − CT3 (F/50) Multiple neck nodes CR CR No −
RT8 (F/47) An axillary node CR CR No − CT4 (M/80) Terminal ileum CRu CRu Yes Mediastinal
 nodes
RT9 (F/76) Tonsil, neck nodes CR CR No − CT5 (M/43) A neck node CR CR No −
RT10 (M/75) An axillary node CR CR No − CT6 (M/72) Nasal cavity PR CR No −
RT11 (F/62) Uterus CR CR No − CT7 (F/50) Terminal ileum CR CR No −
RT12 (M/43) A neck node CRu CR No − CT8 (F/35) A neck node CR CR No −
RT13 (F/41) Tongue and
right cheek
CR CR No − CT9 (F/35) An axillary node CRu CRu No −
RT14 (M/41) Tonsil and
neck nodes
CR CR No − CT10 (F/74) Thyroid and neck nodes PR PR No −
RT15 (F/72) Tongue CR CR No − CT11 (F/56) Terminal ileum CR CR No −
RT16 (M/42) Unilateral
ocular adnexa
CR CR No − CT12 (F/52) Intra-abdominal nodes CR CR No −
RT17 (M/51) Ascending colon CR CR No − CT13 (F/35) Breast and axillary nodes CRu CR Yes Brain
RT18 (F/59) Multiple neck nodes CR CR No − CT14 (F/51) Intra-abdominal nodes CRu CR No −
a)R1 denotes tumor response after initial 3-4 cycles of immunochemotherapy, 
b)R2 denotes response after completion of additional 
immunochemotherapy or radiotherapy, 
c)RT denotes patient treated with subsequent radiotherapy, 
d)CT denotes patient treated with additional 
immunochemotherapy.
Abbreviations: CR, complete response; CRu, CR-unconfirmed; PR, partial response.
Fig. 1. Kaplan-Meier curves of (A) event-free survival and (B) overall survival in all 36 patients with stage I or non-bulky stage II diffuse large B-cell
lymphoma.
5. Comparison of survival according to adverse risk factors
  Among limited disease DLBCL patients, 11 had no adverse 
risk factors. They did not experience any events, and they 
were all alive at the time of analysis. In contrast, patients 
with any of the adverse risk factor had a 3-year EFS of 
65.9% (P=0.047) and a 3-year OS of 80.2% (P=0.135) (Fig. 
3). Further detailed comparisons of survival according to 
stage-modified IPI score (e.g., 0 vs. 1, 2 vs. 3, 4 or 0-2 
vs. 3, 4, etc.) were not possible because of the limited number 
of events and deaths.
DISCUSSION
  The results of this study showed no significant difference 
in survival between the 2 commonly used treatment options Korean J Hematol 2010;45:253-9.
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Table 3. Profile of adverse events during treatment.
Reported adverse event
Subsequent
IFRT (N=22)
Additional
R-CHOP (N=14)
Cumulative hematologic 
 toxicity By CTCAE v.3.0
N (%)
a)
Hemoglobin
Grade 1
Grade 2
Grade 3
Grade 4
13 (59.1)
7 (31.8)
1 (4.5)
1 (4.5)
10 (71.4)
2 (14.3)
2 (14.3)
0
White blood cell count
Grade 1 
Grade 2
Grade 3
Grade 4 
5 (22.7)
6 (27.3)
5 (22.7)
4 (18.2)
1 (7.1)
1 (7.1)
2 (14.3)
5 (35.7)
Absolute neutrophil count
Grade 1
Grade 2
Grade 3
Grade 4
12 (54.5)
2 (9.1)
4 (18.2)
4 (18.2)
2 (14.3)
1 (7.1)
0
11 (78.6)
Platelet
Grade 1
Grade 2
Grade 3
Grade 4
17 (77.3)
4 (18.2)
1 (4.5)
0
9 (64.3)
4 (28.6)
1 (7.1)
0
NF during initial 3 to 4
cycles of R-CHOP
3 (13.6) 5 (35.7)
Admission due to NF 
during additional 
therapy
0 6 (42.9) 3 patients 
had already suffered 
from NF during 
initial R-CHOP)
Admission due to
other cause during 
additional therapy
1 (4.5); due 
 to IFRT-
 induced 
 mucositis
0
Treatment related mortality   0 1 (7.1)
a)The sum of the percentages may not be 100 because of rounding.
Abbreviations: IFRT, involved-field radiation therapy; R-CHOP, 
combination immunochemotherapy consisting of rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisolone; CTCAE 
v.3.0, Common Terminology Criteria for Adverse Events Version 
3.0; NF, neutropenic fever. 
Fig. 2. Kaplan-Meier survival analysis of (A) event-free survival and (B) overall survival according to treatment options.
for DLBCL. Because the prognosis of patients with limited 
disease DLBCL is generally good, neither treatment group 
has yet reached the median EFS or OS in our study. Although 
the patients in both groups showed tolerable toxicities, com-
pared to the patients who underwent IFRT, the patients 
treated with 6-8 cycles of R-CHOP had more frequent epi-
sodes of grade 4 neutropenia and neutropenic fever, which 
resulted in more hospital admissions for antibiotic treatment. 
However, there was no significant difference in TRM.
  Previous randomized trials that compared a brief course 
of CHOP followed by IFRT to CHOP alone have reported 
conflicting data. Miller et al. reported that 3 cycles of CHOP 
followed by IFRT was superior to 8 cycles of CHOP alone 
[3]. In their study, which included 401 patients, the 5-year 
progression-free survival among patients undergoing CHOP 
plus IFRT (N=200) and patients undergoing CHOP alone 
(N=201) was 77% and 64%, respectively (P=0.03), and the 
5-year estimates of OS were 82% and 72%, respectively 
(P=0.02). In contrast, Fillet et al. compared 4 cycles of CHOP 
(N=277) to 4 cycles of CHOP plus IFRT (N=299) in patients 
aged more than 60 years with no other adverse risk factors 
according to the age-adjusted IPI [17]. In their study, patients 
with bulky stage II disease were included. There was no 
difference in EFS or OS at 5 years. With a median follow-up 
time of 7 years, the reported 5-year EFS was 61% for CHOP 
alone versus 64% for CHOP plus IFRT, and the 5-year OS 
was 72% for CHOP alone and 68% for CHOP plus IFRT. 
IFRT appeared to increase treatment-related toxicity. The 
5-year loco-regional failure was 47% without IFRT versus 
21% with IFRT. On the basis of these results, both 3-4 cycles 
of CHOP followed by IFRT and extended cycles of CHOP 
alone have been used for the treatment of patients with 
limited disease NHL.
  Unlike the previously mentioned randomized studies [3, 
17], we retrospectively analyzed data from limited disease 
DLBCL patients treated with R-CHOP. Therefore, there is 
the possibility of uneven distribution of patient characteristics. 
First, if a patient’s lesions were not easily accessible for Korean J Hematol 2010;45:253-9.
258 Junshik Hong, et al. 
Fig. 3. Kaplan-Meier estimates of (A) event-free survival and (B) overall survival according to adverse risk factors.
radiation field simulation or if severe post-radiation compli-
cations were expected, the physician might prefer prolonged 
R-CHOP to subsequent IFRT. However, if a patient had 
a high risk of infection, particularly if the patient had already 
experienced severe neutropenia due to R-CHOP during the 
first 3-4 cycles, the physician might decide to perform IFRT 
instead of additional R-CHOP. As shown in Table 2, 12 
of the 22 patients (54.5%) treated with IFRT had DLBCL 
lesions in their neck nodes, tonsils, or axillary nodes. Ocular 
adnexa (2 patients) are also locations that are easily radiated. 
On the other hand, 6 of the 14 patients (42.9%) treated 
with additional R-CHOP had intestinal lymphomas or in-
tra-abdominal lymph node lesions. Despite the location of 
lesions, 2 patients with intestinal DLBCL underwent sub-
sequent IFRT and 6 patients with tonsilar or cervical and/or 
axillary lymph node DLBCL underwent prolonged R-CHOP 
instead of IFRT, and they showed good outcomes. Known 
poor prognosis might be a factor for considering the use 
of prolonged R-CHOP for treating patients with breast lym-
phoma and multiple regional lymphadenopathies [18].
  Recurrences are predominantly distant rather than lo-
co-regional in patients with DLBCL [19]. Therefore, an at-
tempt was made to reduce the rate of relapse in patients 
with NHL by using an aggressive regimen instead of IFRT. 
Reyes et al. of the Groupe d’Etude des Lymphomes del’Adulte 
(GELA) reported the results of a prospective randomized 
trial that compared 3 cycles of CHOP followed by IFRT 
to an aggressive chemotherapy regimen, a combination of 
doxorubicin, cyclophosphamide, vincristine, bleomycin, and 
prednisone induction (ACVBP) at 2-week intervals, followed 
by high-dose methotrexate, etoposide, and cytarabine con-
solidation [7]. The patients enrolled in the trial were pre-
viously untreated and less than 61 years of age with localized 
stage I or II aggressive NHL (N=647). The investigators con-
cluded that chemotherapy with 3 cycles of ACVBP followed 
by sequential consolidation was superior to 3 cycles of CHOP 
plus radiotherapy. A persistent superior EFS (P=0.002) and 
OS (P=0.01) was found in 574 patients with non-bulky dis-
ease in the study, and regardless of tumor stage and the 
presence or absence of bulky disease, the results were main-
tained in multivariate analysis. The ACVBP studies were 
performed only with patients who had no adverse risk factors. 
Therefore, it is difficult to apply this result to patients with 
risk of infection or poor performance status. Furthermore, 
more toxic events were reported in patients who underwent 
aggressive chemotherapy: 34 episodes of grade 3 infection 
(11%) and 2 episodes of grade 4 infection (1%) occurred 
in the chemotherapy group, compared to 4 episodes of grade 
3 infection in the chemoradiotherapy group (1%). These 
results suggest that eradicating microscopic tumors in limited 
disease lymphomas might not be achieved with 3 cycles 
of CHOP alone and that the role of IFRT is limited to reducing 
the local relapse rate. However, for prolonged chemotherapy, 
the risk of toxicity should be considered according to the 
individual patient’s situation.
  Therefore, whether a short course of systemic therapy 
is effective for reducing the relapse rate remains unconfirmed. 
One study reported that late (≥4 years of disease-free surviv-
al) recurrence in patients with DLBCL was characterized 
by the same clonal abnormalities observed in the primary 
disease [20]; this finding suggests that chemotherapy failed 
to eradicate occult disseminated disease. This study, with 
a long follow up, showed a high late-relapse rate, particularly 
in patients managed with short courses of chemotherapy. 
Considering the median follow-up duration of 4.4 years in 
the study conducted by Miller et al. [3], such late recurrences 
cannot be ruled out. In our study, all 3 patients with relapse 
in the IFRT group showed relapsed tumor outside the radia-
tion port. This might support the need for a long duration 
of systemic therapy to eradicate microscopic disease; how-
ever, the number of relapsed patients was too small to 
analyze.
  In our study, although patients treated with 6-8 cycles 
of R-CHOP tended to be younger and have fewer adverse 
factors, 6 of the 14 patients eventually required hospital 
admission. This result suggests that the risk of neutropenic Korean J Hematol 2010;45:253-9.
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fever should be considered during additional immunochemo-
therapy. Because this study was a retrospective analysis with 
a limited sample size and a relatively short follow-up period, 
a better treatment option for limited disease DLBCL patients 
who are treated with rituximab-based immunochemo-
therapy could not be eventually determined.
  In conclusion, both subsequent IFRT and additional 3-4 
cycles of R-CHOP after 3-4 cycles of R-CHOP immunoche-
motherapy showed excellent survival among patients with 
limited disease DLBCL, if they had no risk factors. Toxicities, 
particularly the risk of neutropenic fever, should be consid-
ered when treating DLBCL patients with rituximab-contain-
ing treatment. A prospective study with a larger number 
of patients should be conducted to determine the optimal 
treatment strategy for DLBCL patients in the rituximab era.
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